Related Experiment Videos
[Meningeal carcinomatosis].
1Arhus Universitetshospital, Arhus Sygehus, Onkologisk Afdeling. sofiasulim@dadlnet.dk
Ugeskrift for Laeger
|September 15, 2005
Summary
Meningeal carcinomatosis (MC) affects 5-8% of advanced cancer patients, with diagnosis via CSF cytology and neuroimaging. Treatment is palliative, offering a poor prognosis and short survival time.
Area of Science:
- Oncology
- Neurology
- Pathology
Context:
- Meningeal carcinomatosis (MC) affects 5-8% of cancer patients, typically those with advanced disease.
- Increased incidence may be due to improved survival from systemic therapies and greater clinical awareness.
- Diagnosis relies on cerebrospinal fluid (CSF) cytology and neuroimaging.
Purpose:
- To summarize the key aspects of meningeal carcinomatosis, including its incidence, diagnosis, prognosis, and treatment.
Summary:
- MC is a serious complication of advanced cancer.
- It presents with a poor prognosis, median survival of 4-11 weeks.
- Treatment is primarily palliative, involving radiotherapy and/or chemotherapy.
Impact:
- Highlights the devastating nature of MC and the need for effective management strategies.
- Informs clinicians about diagnostic methods and palliative care options.
- Underscores the challenges in treating this advanced stage of cancer spread.